NCT06322290 Epidemiological Study on Invasive Bacterial Diseases
| NCT ID | NCT06322290 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Meyer Children's Hospital IRCCS |
| Condition | Invasive Bacterial Diseases (IBD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2021-12-09 |
| Primary Completion | 2031-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2021-12-09 with a primary completion date of 2031-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus influenzae (hemophilus) are among the main bacteria responsible for invasive bacterial diseases (MBIs) that result in severe clinical pictures also characterized by a high frequency of serious complications. Surveillance of infections caused by these pathogens and their distribution by serotypes/serogroups is essential to guide public health interventions, assess epidemiologic trends, monitor any secondary cases, estimate the proportion of preventable cases, identify any vaccine failures, and evaluate the impact of vaccine strategies.The present study aims to study the epidemiology of invasive bacterial diseases, characterize the circulating strains also in order to plan treatment and prevention strategies.
Eligibility Criteria
Inclusion Criteria: * Pediatric and adult patients diagnosed with pneumococcal, meningococcal, and hemophilus MBI Exclusion Criteria: * Other type of bacterial infections.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06322290 clinical trial?
This trial is open to participants of all sexes, aged 1 Day or older, up to 70 Years, studying Invasive Bacterial Diseases (IBD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06322290 currently recruiting?
Yes, NCT06322290 is actively recruiting participants. Contact the research team at chiara.azzari@meyer.it for enrollment information.
Where is the NCT06322290 trial being conducted?
This trial is being conducted at Adria, Italy, Ancona, Italy, Andria, Italy, Bari, Italy and 11 additional locations.
Who is sponsoring the NCT06322290 clinical trial?
NCT06322290 is sponsored by Meyer Children's Hospital IRCCS. The trial plans to enroll 5,000 participants.